Research highlights:
-
A new analysis finds that antidiabetic drugs, SGLT-2 inhibitors, reduce the risk of cardiovascular death and hospitalization for heart failure in high-risk patients with and without type 2 diabetes.
-
Pooled results from 13 pivotal trials of empagliflozin and similar drugs showed study participants who received SGLT-2 inhibitors were 14% less likely to die of cardiovascular disease . Participants treated with these drugs were also 23% less likely to die of cardiovascular disease or be hospitalized for heart failure compared to those who took a placebo.
This data will also be published in The Lancet at the same time.
Embargo until Sunday, November 6, 2022 at 5:26 PM ET / 6:26 PM ET
(new media wire) – November 6, 2022 – CHICAGO SGLT-2 inhibitors, a type of diabetes drug, reduce cardiovascular risk in adults with chronic kidney disease, according to new research presented today at the American Heart Association Scientific Sessions 2022 decreased. A meeting was held. Held in person from November 5-7, 2022 in Chicago, and held online, the conference will provide a global exchange of the latest scientific advances, research, and evidence-based clinical practice updates in cardiovascular science. Great event.
“Many studies on empagliflozin and other similar drugs called SGLT-2 inhibitors (sodium-glucose cotransporter-2 inhibitors) demonstrate that these drugs are safe for people with type 2 diabetes. D., Associate Professor, Population Health Research Unit, Medical Research Council, University of Oxford, Oxford Population Health, UK “And there is now very good evidence to reduce the likelihood of death from vascular disease and hospitalization for heart failure. Among people with chronic kidney disease, heart failure, or type 2 diabetes and cardiovascular disease. hoping.”
The researchers combined results from 13 pivotal clinical trials of SGLT-2 inhibitors to determine whether participants with or without type 2 diabetes had progression of kidney disease, acute kidney injury, cardiovascular death or heart failure. We examined the effect on hospitalization. According to Preiss, analyzes confirmed significant benefits of his SGLT-2 inhibitors for both major cardiovascular and kidney disease outcomes.
-
SGLT-2 inhibitors reduced the risk of cardiovascular death by 14%, with similar results among participants with and without type 2 diabetes.
-
SGLT-2 inhibitors also reduced the risk of cardiovascular death or hospitalization for heart failure by 23%, with similar results among participants with and without type 2 diabetes.
-
The overall risk of kidney disease progression was reduced by 37%, with similar effects among participants regardless of type 2 diabetes status.
-
Based on trial data, 34 with diabetes and 22 without diabetes avoided cardiovascular death or heart failure hospitalization when 1,000 participants with heart failure were treated for one year.
-
For every 1,000 participants with chronic kidney disease treated for one year, 11 with diabetes and 15 without diabetes avoided exacerbation of kidney disease.
The meta-analysis included results from the EMPA-KIDNEY trial, the largest study evaluating the use of SGLT-2 inhibitors in participants with chronic kidney disease. Previous studies have associated this drug with a lower risk of hospitalization. heart failure Reduced risk of worsening kidney disease in patients with type 2 diabetes. “The unknown is whether the drug would have the same protective effect in people who have not been diagnosed with type 2 diabetes,” Preiss said.
EMPA-KIDNEY researchers enrolled 6,609 study participants in eight countries: Germany, USA, UK, China, Malaysia, Japan, Canada and Italy. The average age of the participants he was 64, more than half were white, 36% were Asian, and 4% were black. All participants had evidence of kidney disease for at least 3 months. More than 25% had cardiovascular disease. Less than half of them had type 2 diabetes. Between May 2019 and April 2021, participants were randomly assigned to empagliflozin or placebo. Follow-up averaged 2 years.
Results from the EMPA-KIDNEY trial, published two days ago on November 4, 2022, showed a 28% reduction in the risk of worsening kidney disease and cardiovascular death among participants in the empagliflozin arm showed. or no type 2 diabetes. The incidence of cardiovascular events was lower than expected. Although the reduction in major cardiovascular events with empagliflozin treatment was not statistically significant in the trial, the results of these results were fully consistent with those of other trials.
“Our results suggest that SGLT-2 inhibitors, such as empagliflozin, may be an effective treatment option for reducing the risk of kidney disease progression and cardiovascular complications in patients with chronic kidney disease, with or without type 2 disease. It suggests that it should be offered to all adults who could benefit from it, whether they have diabetes or not,” Preiss said.
Co-authors are William Herrington (MD) and Richard Haynes (DM) on behalf of the Oxford Population Health Renal Studies Group and the SGLT2 Meta-analysis Cardio-renal Trialists’ Consortium (SMART-C). Author disclosures are provided in the abstract.
This study was funded by core funding from the UK Medical Research Council to the University of Oxford’s Medical Research Council Population and Health Research Unit. EMPA-KIDNEY was funded by Boehringer Ingelheim and his Eli Lilly and Company.
Research statements and conclusions presented at an American Heart Association scientific conference are solely those of the study authors and do not necessarily reflect the policies or positions of the association. The Association makes no representations or warranties as to their accuracy or reliability. Abstracts presented at the Society’s scientific meetings are not peer-reviewed. Rather, they are curated by an independent review board and considered on the basis of their potential to add to the diversity of scientific issues and views discussed at the conference. Findings are considered preliminary until publication as a full manuscript in a peer-reviewed scientific journal.
The association receives funding primarily from individuals. Foundations and companies (including pharmaceuticals, device manufacturers, and other companies) also make donations to fund specific programs and events of the association. The Society has strict policies to prevent these relationships from affecting the content of science. Income from pharmaceutical companies, biotech companies, device manufacturers, health insurers, and the association’s overall financial information are available. here.
Additional resources:
of the American Heart Association Science Session 2022 is the premier event for the global exchange of the latest scientific advances, research and evidence-based clinical practice updates in cardiovascular science. The three-day conference will take place from Saturday to Monday, November 5-7, 2022 with more than 500 sessions focused on groundbreaking updates in basic, clinical and demographic cardiovascular science. increase. Experts from around the world will be able to convene virtually to participate in basic, clinical and population science presentations, discussions and curricula to shape the future of cardiovascular science and medicine, including prevention and quality improvement. During the three-day conference, attendees will have exclusive access to his over 4,000 original research publications and earn Continuing Medical Education (CME), Continuing Education (CE), or Maintained Credential (MOC) credits for educational sessions I can do it.Join Scientific Sessions 2022 on social media #AHA22.
About the American Heart Association
The American Heart Association is a constant force in helping the world live longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Working with dozens of organizations and supported by millions of volunteers, we fund groundbreaking research, advocate for public health, and share life-saving resources. The Dallas-based organization has been a leading source of health information for nearly a century.connect with us heart.org, Facebook, twitter Or call 1-800-AHA-USA1.
###
Media Inquiries and AHA Professional Perspectives:
AHA Communications & Media Relations in Dallas: 214-706-1173; [email protected]
Bridgette McNeill: 214-706-1135; [email protected]
General Inquiries: 1-800-AHA-USA1 (242-8721)
heart.org When stroke.org
